Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2022

View Archived Issues

FGFR2-selective inhibitor CGT-0292 shows promise for treating hyperphosphatemia

Lieber Institute, Johns Hopkins University present DNA-directed RNA polymerase I inhibitors

New protein kinase inhibitors described by Voronoi, B2SBIO and Voronoi Bio

Kinnate Biopharma discovers RAF kinase inhibitors

Asan Foundation, DGMIF, University of Ulsan describe new EHMT2 inhibitors

Neuropilin-2 suppression is possible approach for treating lymphatic malformations

In vivo imaging of integrin beta-2 activation enabled with humanized integrin beta-2 knockin mice

CFT-8634, a novel BRD9 degrader with promising efficacy in PDX models of synovial sarcoma

AACR 2022: Understanding cancer's brain is new microenvironment frontier

Preclinical evaluation of EPC-001, a fully human anti-CD19 and CD22 bispecific tandem CAR-T

GCN2 is activated in prostate cancer and shows promise as therapeutic target

Gb Sciences' cannabinoid-containing formulations to be tested in rodent models of Parkinson's

MYMD-1 shows anti-inflammatory effects in comparative study in rheumatoid arthritis model

ABN-501, a novel antibody targeting CLDN3, for cancer immunotherapy

Engitix expands collaboration with Takeda to include therapeutics for fibrostenotic IBD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...